t cell engager - Robuta Search

https://www.pharmaceutical-technology.com/news/candid-therapeutics-signs-925m-t-cell-engager-deal-with-wuxi-biologics/ Candid Therapeutics signs $925m T-cell engager deal with WuXi Biologics - Pharmaceutical Technology Jan 9, 2025 - Candid plans to conduct first-in-human studies in 2026 as it continues its T-cell engager deal drive. t cell engager https://www.biospace.com/xencor-regains-cd20-x-cd3-bispecific-t-cell-engager Xencor Regains CD20 x CD3 Bispecific T-Cell Engager - BioSpace Jun 14, 2024 - Xencor, Inc. announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1... bispecific t cell engager regains cd20 x cd3 https://www.aacr.org/patients-caregivers/progress-against-cancer/t-cell-engager-approved-for-aggressive-lung-cancer/ T-cell Engager Approved for Aggressive Lung Cancer | Research | AACR Jan 31, 2026 - The FDA has granted tarlatamab-dlle a traditional approval for previously treated adults with extensive-stage small cell lung cancer. t cell engager lung cancer approved aggressive research https://www.biospace.com/abcellera-announces-two-t-cell-engager-presentations-at-sitc-2023 AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 - BioSpace Sep 27, 2023 - AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer (SITC)... t cell engager abcellera announces two https://www.fiercebiotech.com/biotech/januxs-t-cell-engager-makes-waves-again-latest-data-drop-solidifying-best-class-spot-late Janux's T-cell engager makes waves, again, with new data drop Dec 3, 2024 - Among patients with heavily pretreated prostate cancer, all 16 patients who received JANX007 achieved a 50% decline in prostate-specific antigens. t cell engager